Gilead Sciences Inc. [NASDAQ: GILD] price surged by 0.05 percent to reach at $0.03. The company report on February 18, 2021 that Gilead Sciences to Present at Upcoming Investor Conferences.
Gilead Sciences, Inc. (Nasdaq: GILD) announced that its executives will be speaking at the following investor conferences:.
SVB Leerink Global Healthcare Conference on Thursday, February 25, 2021 at 1:40 p.m. EST.
A sum of 6523595 shares traded at recent session while its average daily volume was at 9.07M shares. Gilead Sciences Inc. shares reached a high of $64.23 and dropped to a low of $62.81 until finishing in the latest session at $63.71.
The one-year GILD stock forecast points to a potential upside of 14.03. The average equity rating for GILD stock is currently 2.40, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Gilead Sciences Inc. [GILD]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for GILD shares is $74.11 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on GILD stock is a recommendation set at 2.40. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Morgan Stanley have made an estimate for Gilead Sciences Inc. shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on January 19, 2021. The new note on the price target was released on January 04, 2021, representing the official price target for Gilead Sciences Inc. stock. Previously, the target price had yet another raise to $67, while Morgan Stanley analysts kept a Equal-Weight rating on GILD stock.
The Average True Range (ATR) for Gilead Sciences Inc. is set at 1.56, with the Price to Sales ratio for GILD stock in the period of the last 12 months amounting to 3.28. The Price to Book ratio for the last quarter was 4.58, with the Price to Cash per share for the same quarter was set at 18.87. Price to Free Cash Flow for GILD in the course of the last twelve months was 15.64 with Quick ratio for the last quarter at 3.10.
GILD Stock Performance Analysis:
Gilead Sciences Inc. [GILD] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -2.14. With this latest performance, GILD shares dropped by -6.53% in over the last four-week period, additionally sinking by -3.59% over the last 6 months – not to mention a drop of -9.12% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for GILD stock in for the last two-week period is set at 43.56, with the RSI for the last a single of trading hit 35.51, and the three-weeks RSI is set at 47.65 for Gilead Sciences Inc. [GILD]. The present Moving Average for the last 50 days of trading for this stock 63.02, while it was recorded at 64.22 for the last single week of trading, and 66.75 for the last 200 days.
Insight into Gilead Sciences Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Gilead Sciences Inc. [GILD] shares currently have an operating margin of +42.49 and a Gross Margin at +81.74. Gilead Sciences Inc.’s Net Margin is presently recorded at +0.50.
Return on Equity for this stock inclined to 0.60, with Return on Assets sitting at 0.19.
Receivables Turnover for the company is 5.83 with a Total Asset Turnover recorded at a value of 0.38.Gilead Sciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.10 and a Current Ratio set at 3.30.
GILD Stock EPS
With the latest financial reports released by the company, Gilead Sciences Inc. posted 1.68/share EPS, while the average EPS was predicted by analysts to be reported at 1.57/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 7.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for GILD. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Gilead Sciences Inc. go to 2.80%.
Gilead Sciences Inc. [GILD] Insider Position Details
There are presently around $60,934 million, or 79.90% of GILD stock, in the hands of institutional investors. The top three institutional holders of GILD stocks are: CAPITAL RESEARCH GLOBAL INVESTORS with ownership of 121,672,399, which is approximately 3.893% of the company’s market cap and around 0.11% of the total institutional ownership; BLACKROCK INC., holding 111,183,334 shares of the stock with an approximate value of $7.08 billion in GILD stocks shares; and VANGUARD GROUP INC, currently with $6.55 billion in GILD stock with ownership of nearly 0.063% of the company’s market capitalization.
Positions in Gilead Sciences Inc. stocks held by institutional investors increased at the end of February and at the time of the February reporting period, where 709 institutional holders increased their position in Gilead Sciences Inc. [NASDAQ:GILD] by around 51,052,149 shares. Additionally, 857 investors decreased positions by around 57,168,098 shares, while 149 investors held positions by with 848,204,841 shares. The mentioned changes placed institutional holdings at 956,425,088 shares, according to the latest SEC report filing. GILD stock had 184 new institutional investments in for a total of 6,325,549 shares, while 161 institutional investors sold positions of 5,982,304 shares during the same period.